Creating a new treatment for Alzheimer's disease
Official title: Development of a Novel Alzheimer's Disease Therapeutic
Funded at Aphios Corporation · NIH-10920778 · Data updated 2026-11-12
This study is exploring a new way to help people with Alzheimer's by using tiny particles to deliver a safe, existing medication that may reduce brain inflammation and improve memory, and they will first test it in the lab and on animals before considering it for human trials.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aphios Corporation NIH-funded |
| Lab location | 1 site (Woburn, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $504,732 |
| NIH project number | 1R43AG085863-01A1 |
| Project ID | NIH-10920778 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are experiencing symptoms of Alzheimer's disease.
✕Less likely to help
Patients with other forms of dementia or those who are not diagnosed with Alzheimer's disease may not benefit from this research.
What this research studies
This research focuses on developing a novel therapeutic approach for Alzheimer's disease by targeting inflammation in the brain. The team will create nanoparticles that encapsulate an FDA-approved drug aimed at the CCR5 receptor, which is linked to memory issues in aging. They will test these nanoparticles in laboratory models to assess their effectiveness in reducing brain inflammation and improving cognitive function. The research will progress through various phases, including in vitro studies and animal testing, to ensure safety and efficacy before potential human trials.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that alleviates symptoms of Alzheimer's disease and improves memory function.
How similar studies have gone: Previous research has shown promise in targeting inflammation in Alzheimer's disease, but this specific approach using nanoparticles is relatively novel.
Where this research is happening
-
Aphios Corporation
Woburn, United States Active
Researchers
- Principal investigator: Castor, Trevor P. — Aphios Corporation
- Study coordinator: Castor, Trevor P.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.